NCT07478536

Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)

Multicenter Validation of the Stockholm3 Test on Men on Active Surveillance: the CHAS3-Trial

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 350 (estimated)
• Sponsor: Insel Gruppe AG, University Hospital Bern · Academic / Other
• Sex: Male
• Age: —
• Healthy volunteers: Not accepted

Summary

The CHAS3 trial studies whether the Stockholm3 blood test can reliably detect if prostate cancer becomes more aggressive in men who are being carefully monitored instead of treated right away (active surveillance). The goal is to see if this test can help doctors safely follow patients with fewer invasive procedures, such as repeated biopsies.

Detailed description

The CHAS3 trial is a study carried out at several hospitals that follows men with prostate cancer who are being closely monitored through active surveillance. The study looks at how well the Stockholm3 blood test can predict whether the cancer has become more serious when the men later have their scheduled follow-up biopsy. Men who are already on active surveillance and planned for a routine biopsy may be invited to join. Participants must be alive and must not have started any treatments such as surgery, radiation, hormone therapy, or chemotherapy. To avoid extra procedures, any study samples will be taken at the same time as the patient's regular follow-up visits.

Conditions

• Prostate Cancer
• Active Surveillance for Prostate Cancer

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Stockholm3	Predictive value of Stockholm3 test in a prostate cancer cohort on Active Surveillance (AS) for upgrading on re-biopsy

Timeline

• Start date: 2026-04-01
• Primary completion: 2028-03-31
• Completion: 2028-08-31
• First posted: 2026-03-17
• Last updated: 2026-03-30

Locations

1 site across 1 country: Switzerland